Norovirus infection cost-effectiveness of therapy: Difference between revisions

Jump to navigation Jump to search
m (Changes made per Mahshid's request)
 
(One intermediate revision by the same user not shown)
Line 4: Line 4:
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.


== References ==
==Overview==
The cost of Norovirus prevention and therapy will save long lasting burden of the infection in the susceptible population. 
==Cost effectiveness of Therapy==
Noroviruses are a well-known major cause of [[acute gastroenteritis]] in the developed world, yet our ability to prevent and control infection is limited. Recent studies have demonstrated that a typical infection may present itself as acute in the normal population, while long-lasting (i.e. years) in the [[immunocompromised host]]. These patents  and those regularly exposed to infectious material, care workers and others, would benefit greatly from the development of a vaccine or antiviral therapy.
Considering the the [[Socio-economic status|socio-economic]] impact of norovirus infection, the case for the event of antiviral approaches and effective vaccines is powerful. There  have been vaccines proven efficient against noroviruses in cell culture and a minimum of one in a the mouse model, non of which have made it through to clinical use for the [[treatment]] or [[prevention]] of norovirus infection. Since the therapy is to target intestinal pathogens, there's a big problem related to the stability of the vaccine in this rather harsh environment as well as its delivery to the replication site. Subsequently, there are variety of great obstacles to overcome for the utilization of those inhibitors in an exceedingly clinical setting.<ref name="pmid24199805">{{cite journal| author=Arias A, Emmott E, Vashist S, Goodfellow I| title=Progress towards the prevention and treatment of norovirus infections. | journal=Future Microbiol | year= 2013 | volume= 8 | issue= 11 | pages= 1475-87 | pmid=24199805 | doi=10.2217/fmb.13.109 | pmc=3904215 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24199805  }} </ref>
==References==
{{Reflist|2}}
{{Reflist|2}}



Latest revision as of 15:03, 29 January 2021

Norovirus infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Norovirus infection from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Norovirus infection cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Norovirus infection cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Norovirus infection cost-effectiveness of therapy

CDC on Norovirus infection cost-effectiveness of therapy

Norovirus infection cost-effectiveness of therapy in the news

Blogs on Norovirus infection cost-effectiveness of therapy

Directions to Hospitals Treating Norovirus infection

Risk calculators and risk factors for Norovirus infection cost-effectiveness of therapy

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

The cost of Norovirus prevention and therapy will save long lasting burden of the infection in the susceptible population.

Cost effectiveness of Therapy

Noroviruses are a well-known major cause of acute gastroenteritis in the developed world, yet our ability to prevent and control infection is limited. Recent studies have demonstrated that a typical infection may present itself as acute in the normal population, while long-lasting (i.e. years) in the immunocompromised host. These patents and those regularly exposed to infectious material, care workers and others, would benefit greatly from the development of a vaccine or antiviral therapy. Considering the the socio-economic impact of norovirus infection, the case for the event of antiviral approaches and effective vaccines is powerful. There have been vaccines proven efficient against noroviruses in cell culture and a minimum of one in a the mouse model, non of which have made it through to clinical use for the treatment or prevention of norovirus infection. Since the therapy is to target intestinal pathogens, there's a big problem related to the stability of the vaccine in this rather harsh environment as well as its delivery to the replication site. Subsequently, there are variety of great obstacles to overcome for the utilization of those inhibitors in an exceedingly clinical setting.[1]

References

  1. Arias A, Emmott E, Vashist S, Goodfellow I (2013). "Progress towards the prevention and treatment of norovirus infections". Future Microbiol. 8 (11): 1475–87. doi:10.2217/fmb.13.109. PMC 3904215. PMID 24199805.


Template:WikiDoc Sources